The BOLERO-2 study confirms everolimus and exemestane in ER/PR+ advanced breast cancer improves PFS
26 Sep 2011
The BOLERO-2 study confirms everolimus and exemestane in ER/PR+ advanced breast cancer improves PFS
Trastuzumab emtansine, Phase II trial for HER2
Radiotherapy between or during chemo cycles for breast cancer
Denosumab delays metastases for prostate cancer
Zoledronic acid reduces recurrence of breast cancer
Experimenting with smaller, faster clinical trials
Frequency of biopsies for breast cancer tumours
4HBR chemoprevention in BRCA positive women
Genetic basis of cancer predisposition
Genetic mutations as causes of cancer
Chemotherapy infusions directly to organs
Phase III trial of an alpha-pharmaceutical